Incidence of amyotrophic lateral sclerosis in Chile.

Amyotrophic lateral sclerosis incidence motor neuron disease survival

Journal

Amyotrophic lateral sclerosis & frontotemporal degeneration
ISSN: 2167-9223
Titre abrégé: Amyotroph Lateral Scler Frontotemporal Degener
Pays: England
ID NLM: 101587185

Informations de publication

Date de publication:
20 Mar 2024
Historique:
medline: 20 3 2024
pubmed: 20 3 2024
entrez: 20 3 2024
Statut: aheadofprint

Résumé

This study aimed to estimate amyotrophic lateral sclerosis (ALS) incidence and survival rates in the Metropolitan region of Chile. We conducted a cohort study of ALS cases in the Metropolitan Region from 2016 to 2019. A total of 219 ALS patients were recruited from Corporación ELA-Chile registry, in collaboration with neurologists from Sociedad de Neurología, Psiquiatría y Neurocirugía de Chile. We calculated incidence rates by sex and age and determined median survival from onset and diagnosis. Survival analysis used the Kaplan-Meier statistic, estimating hazard ratios for age, sex, time from symptom onset and from diagnosis using a Weibull regression model. All analyses were done using R 4.1.0. Overall, ALS diagnosis incidence was 0.97 cases per 100,000 inhabitants, peaking in the 70-79 age group and declining thereafter. The male-to-female ratio was 1.23. The median time to death from diagnosis was 2.3 years (95% confidence interval [CI]: 1.9-2.5), and from the first symptom, it was 3.1 years (95% CI: 2.8-3.5). This is the first population-based study reporting ALS incidence and survival rates in Chile's Metropolitan region. Incidence resembled other Latin American studies. Median survival from diagnosis and from the first symptom were in line with previous findings. Our results corroborated lower ALS rates in Latin America, consistent with prior research.

Identifiants

pubmed: 38506473
doi: 10.1080/21678421.2024.2329706
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-5

Auteurs

Patricia Lillo (P)

Departamento de Neurología Sur, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Geroscience Center for Brain Health and Metabolism (GERO), Santiago, Chile.
Unidad de Neurología, Hospital San José, SSMN, Santiago, Chile.

Pedro Zitko (P)

Departamento de Salud Global, Escuela de Salud Pública, Universidad de Chile, Santiago, Chile.

Gladys Godoy-Reyes (G)

Departamento de Neurología Sur, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Servicio de Neurología, Complejo Asistencial Barros Luco, Servicio de Salud Metropolitano Sur, Santiago, Chile.

Gabriela Asenjo (G)

Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

David Sáez (D)

Departamento de Neurología Sur, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Servicio de Neurología, Complejo Asistencial Barros Luco, Servicio de Salud Metropolitano Sur, Santiago, Chile.

Gonzalo Cea (G)

Departamento de Neurología Sur, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

Pamela Navarrete (P)

Departamento de Neurología Sur, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

Daniel Valenzuela (D)

Departamento de Neurología Sur, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Servicio de Neurología, Complejo Asistencial Barros Luco, Servicio de Salud Metropolitano Sur, Santiago, Chile.

Ricardo Hughes (R)

Unidad de Neurología, Hospital San José, SSMN, Santiago, Chile.
Servicio de Neurología, Hospital Clínico Universidad de Chile, Santiago, Chile.

Mark Heverin (M)

Academic Unit of Neurology, Clinical Medicine, Trinity College Dublin, Dublin, Ireland, and.

Giancarlo Logroscino (G)

Center for Neurodegenerative Diseases and the Aging Brain. Fondazione "Card. G. Panico" Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari "Aldo Moro", Bari, Italy.

Orla Hardiman (O)

Academic Unit of Neurology, Clinical Medicine, Trinity College Dublin, Dublin, Ireland, and.

Classifications MeSH